ANGELIQ InfoSite

References

  1. Data on File, Berlex Inc.
  2. ANGELIQ [Package Insert]. Wayne, NJ; Berlex Inc; 2005.
  3. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: A randomized, double-blind, multicenter trial. Menopause. 2005;12:716-727.
  4. Krattenmacher R. Drospirenone: Pharmacology and pharmacokinetics. Contraception. 2000;62:29-38.
  5. The North American Menopause Society. Bioidentical Hormone Therapy. Available at http://www.menopause.org/bioidentical.htm. Accessed July 12, 2006.
  6. Archer DF, Fischer LA, Rich D, et al. Estrace® vs Premarin® for treatment of menopausal symptoms: dosage comparison study. Adv Ther. 1992;9:21-31
  7. The Gallup Organization, Inc. The 2000 Gallup Study of Women's Experiences with Hormone Replacement Therapy. Princeton, NJ: Multi-Sponsor Surveys, Inc. Conducted for Berlex Laboratories, April 2000.
  8. Lobo RA. Progestogens: New approaches. Medical Science Symposia Series. 2002;17:167-172.
  9. Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17B-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000;95:726-731.